Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 5, 2012 - Issue 5
Submit an article Journal homepage
105
Views
1
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Early response of ceftaroline fosamil in the treatment of soft-tissue infections

Christopher Giuliano Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, St John Hospital and Medical Center, Detroit, MI 48201, USA; Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, St John Hospital and Medical Center, Detroit, MI 48201, USA
,
Pramodini B Kale-Pradhan Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, St John Hospital and Medical Center, Detroit, MI 48201, USA; Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, St John Hospital and Medical Center, Detroit, MI 48201, USA
&
Leonard B Johnson Division of Infectious Diseases, St John Hospital and Medical Center, School of Medicine, Wayne State University, Detroit, MI 48201, USA. [email protected]; Division of Infectious Diseases, St John Hospital and Medical Center, School of Medicine, Wayne State University, Detroit, MI 48201, USA. [email protected]
Pages 509-512 | Published online: 10 Jan 2014

References

  • Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51(6), 641–650 (2010).
  • Dryden MS. Skin and soft tissue infection: microbiology and epidemiology. Int. J. Antimicrob. Agents 34(Suppl. 1), S2–S7 (2009).
  • Stevens DL, Bisno AL, Chambers HF et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41(10), 1373–1406 (2005).
  • Moran GJ, Krishnadasan A, Gorwitz RJ et al.; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666–674 (2006).
  • Wilcox MH, Corey GR, Talbot Gh, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob. Chemother. 65(Suppl. 4), iv53–iv65 (2010).
  • Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl. 4), iv41–iv51 (2010).
  • Snodgrass WR, Anderson T. Sulphanilamide in the treatment of Erysipelas. Br. Med. J. 2(4014), 1156–1159 (1937).
  • Snodgrass WR, Anderson T. Prontosil in Erysipelas. Br. Med. J. 2(3993), 101–104 (1937).
  • Friedland HD, O’Neal T, Biek D et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two Phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 56(5), 2231–2236 (2012).
  • Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53(11), 4712–4717 (2009).
  • Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51(9), 3397–3400 (2007).
  • Cottanoud P, Acosta F, Biek D, Cottagnoud M, Leib S. Ceftaroline fosamil against penicillin-sensitive and penicillin-resistant Streptococcus pneumoniae in an experimental meningitis model. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Boston, MA, USA, 12–15 September 2010.
  • Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl. 4), iv67–iv71 (2010).
  • Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 52(9), 1156–1163 (2011).
  • Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(Suppl. 4), S341–S345 (2004).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.